Loading...

PODCAST

pharmaphorum Podcast

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for

science life sciences

All Episodes

29:31

Bioconvergence & future human health, with Shai Melcer

pharmaphorum Podcast ·

2026/10/01

Bioconvergence is a multidisciplinary research and development approach that merges technologies from biology, engineering, and computation, providing solutions in medicine, food, agriculture, manufacturing, climate, and more.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shai Melcer, head of the national bioconvergence programme at Israel Innovation Authority, for a conversation exploring bioconvergence broadly. Melcer discusses the foundations, goes into detail about

en-us

30:33

AI-enabled pharmacovigilance, with Updesh Dosanjh

pharmaphorum Podcast ·

2026/09/24

Artificial intelligence is dramatically transforming the landscape for every part of pharma. One area where AI is both essential to implement and important to get right is pharmacovigilance, the group concerned with monitoring and maintaining patient safety.In today's pharmaphorum podcast, sponsored by IQVIA Safety Solutions, host Jonah Comstock speaks with Updesh Dosanjh, IQVIA commercialisation lead for safety technology, about how and why the role of AI in pharmacovigilance is changing, as

en-us

18:49

Getting predictive technologies to patients, with Concr

pharmaphorum Podcast ·

2026/09/22

Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical trials in a significant shift in how regulators think about predictive medicine. In a new pharmaphorum podcast, Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static, one-test-one-answer diagnostics, as well as the potential of digital twins, and how, if regulators keep approving AI medical tools the way they

en-us

18:21

Europe for life sciences and for patients, with BeOne...

pharmaphorum Podcast ·

2026/09/15

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*Europe continues to offer major life sciences advantages: deep scientific talent, strong clinical expertise, mature research infrastructure, and significant manufacturing capability. Indeed, biotech companies continue to invest in Europe as a long-term hub for scientific innovation, clinical research, and economic growth. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo

en-us

15:39

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

pharmaphorum Podcast ·

2026/09/08

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*When it comes to digital innovation and AI, consideration of using and implementing such responsibly and ethically ever more becomes forefront. But how can pharma lead the way in ethical AI and trust-driven innovation? In a new pharmaphorum podcast, Erik Janssen, head of digital care transformation at UCB, joins web editor Nicole Raleigh for a conversation on responsible digital innovation and ethical

en-us

16:20

Delivering prevention at scale, PA Consulting’s James...

pharmaphorum Podcast ·

2026/08/25

Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at scale isn’t in place.In a new episode of the podcast, pharmaphorum spoke with James Davis, a healthcare expert at PA Consulting, for a conversation on the digital foundations needed to unlock a prevention first NHS. Davis also discusses the initiatives with the biggest near term impact, what NHS leaders are worried about, and

en-us

35:54

Understanding Operation Trialblazer, with Dr Harpreet...

pharmaphorum Podcast ·

2026/08/19

For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lighter regulatory burden in places like China and Australia. The industry has long urged the US government to take some action to make it more attractive to bring these trials back to the States. That's the broad idea behind Operation TRIALBLAZER, a campaign launched this summer by HHS and the FDA.On today's podcast, host Jonah

en-us

15:15

Prevent-Stop-Cure: Diagnostics & chronic liver...

pharmaphorum Podcast ·

2026/08/04

Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are identified, not just what therapies are available.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lee Lehman Becker, Roche’s global head of healthcare insights at Roche Information Solutions (RIS), for a discussion of the liver disease epidemic that is being diagnosed too late and driving a growing health

en-us

29:59

Policy in Focus: What’s new with CMS drug price...

pharmaphorum Podcast ·

2026/07/30

The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the agency has put out new draft guidance codifying and, in some cases, modifying the fine print of the controversial law. They’ve also recently issued additional draft guidance on how they’ll handle the imminent introduction of Part B drugs into the programme.Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum

en-us

16:40

CAMP4 on a new class of ASO in gene under expression

pharmaphorum Podcast ·

2026/07/21

SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor symptoms.In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, about antisense oligonucleotides (or ASOs) - medicines designed to selectively restore natural protein production in diseases caused by gene under expression. Gold discusses the space and CAMP4’s

en-us

20:14

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

pharmaphorum Podcast ·

2026/07/14

The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how the wave could differ. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, about whether the current US biotech M&A surge will indeed extend into Europe. The conversation

en-us

15:16

Purespring on nephrology & gene therapy in kidney...

pharmaphorum Podcast ·

2026/07/07

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease. Indeed, Purespring’s lead programme is the podocyte-targeted gene therapy

en-us

15:24

Parexel: Flawless execution, policy shifts &...

pharmaphorum Podcast ·

2026/06/30

Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal. The conversation touches upon regulatory strategy and evolving policy shifts, trial design and execution – and the importance of patient

en-us

13:22

Citius’ Leonard Mazur talks targeted immune therapy...

pharmaphorum Podcast ·

2026/06/23

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first

en-us

14:33

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

pharmaphorum Podcast ·

2026/06/17

The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within precision oncology and molecular imaging, and the need for specialised CDMOs when it comes to the intricate nature of radiopharmaceutical manufacturing.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cavey, CEO of ITM, about current and future radiopharmaceutical

en-us

13:13

Biosimilars & patient access independent of...

pharmaphorum Podcast ·

2026/06/10

2026 is the year of a major wave of pharmaceutical patent expirations, with numerous blockbuster drugs – spanning diabetes, immunology, cardiovascular, oncology, and other therapeutic areas – on the verge of losing market exclusivity.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rebecca Guntern, chief commercial officer at Sandoz, for a conversation on the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent. Guntern discusses why the

en-us

23:30

Towards a healthier world: Momentum in UK health...

pharmaphorum Podcast ·

2026/06/02

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson, about what delivery will look like in practice when it comes to the National Cancer Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.The conversation ranges what comes next following the clear policy direction of the Plans, including how the system can move from ambition to implementation, particularly in ensuring innovation is adopted

en-us

18:13

Trustworthy and novel AI in clinical trial planning,...

pharmaphorum Podcast ·

2026/05/26

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant strategy recommendations. Kaneta discusses AI in drug trials and commercialisation and just what’s possible when clinical AI has access to a data set robust enough to allow it to make real strategic recommendations. Kaneta also touches upon why patient-level data is pharma's most important asset in the AI race

en-us

15:40

The cardio-renal-metabolic space and obesity as a...

pharmaphorum Podcast ·

2026/05/19

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism, at Boehringer Ingelheim.The conversation explores the crisis beyond obesity that many clinicians and health systems are now grappling with: that obesity can’t be treated as a short-term, weight-loss lifestyle issue. Rather, it needs to be managed as a complex, chronic, multi-organ disease. Younes discusses how liver disease is

en-us

18:06

On the power of T-cells, with Cedrik Britten

pharmaphorum Podcast ·

2026/05/12

In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell immunotherapies.Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. And to do so safely and effectively requires deep expertise in immunology, drug development, and beyond. Britten explains how finding the right cancer target is only half the equation – the other half is

en-us

358 results

Similar Podcasts

The Deep Dive Lab: Unraveling Materials Science

Son Hoang

New Books in Political Science

New Books Network

Station 151

Pale Matter | Realm

Beyond the Divide

Koala Moon

StarTalk with Neil deGrasse Tyson

Neil deGrasse Tyson